Neurologix, Inc. Signs Strategic License Agreement For Component Of Its Parkinson's Gene Therapy Product

FORT LEE, N.J.--(BUSINESS WIRE)--Aug. 7, 2006--Neurologix, Inc. (OTCBB: NRGX - News), a biotech company committed to developing innovative gene therapies for the brain and central nervous system, announced today that it has entered into a licensing agreement with a subsidiary of Diamyd Medical (SWEDEN OMXS: DIAM B) (USA ADR: DMYDY), a biotechnology company based in Stockholm, Sweden, and Pittsburgh, PA.

Back to news